Further, our results suggest that Ink4a/Arf(−/−) EGFRvIII glioblastomas that acquired resistance to EGFR inhibition retain oncogenic stress that requiring PLK1 compensation (Figure 7E, upper panel). Here, CDKN2A is linked to glioblastoma.